To assess magnetic resonance imaging (MRI) and pathologic staging after neoadjuvant therapy for rectal cancer in a prospectively enrolled, multicenter study.
INTRODUCTION
In rectal cancer, long-course radiotherapy or preoperative combination chemoradiotherapy together with total mesorectal excision (TME) surgery is associated with improved curative surgery and reduced local recurrence (LR). 1 Cross-sectional imaging techniques, including magnetic resonance imaging (MRI), enable appropriate selection of patients on the basis of assessment of locally advanced disease and the relationship of tumor to the potential resection margin. 2 Assessment of treatment efficacy has principally relied on histopathologic assessment of irradiated specimens after surgery. These studies have shown that post-treatment pathologic T and N stage (ypT and ypN, respectively) can predict LR, diseasefree survival (DFS), and overall survival (OS). 3 It has also been observed that qualitative assessment of the degree of fibrosis in the pathology specimen can be used to derive a tumor regression grading (TRG) system, 4,5 which predicts OS and is considered an important prognostic predictor for DFS. 6 Highresolution MRI has been used to assess tumor response before surgical resection, but the relevance of post-treatment MRI assessment in predicting survival outcomes has not been investigated. [7] [8] [9] [10] Furthermore, by applying the principles of histopathologic grading and by exploiting the characteristic MRI low signal intensity appearances of
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© 2011 by American Society of Clinical Oncology fibrosis, it has been possible to develop a similar MRI-based TRG system. 11 In 2002, a prospective study evaluated the diagnostic accuracy of MRI staging in a consecutive series of patients with biopsy-proven rectal cancer undergoing TME surgery with histopathology as the reference standard. We now report a planned subgroup analysis of MRI assessment of post-treatment scans in patients enrolled on this follow-up study. 9 The aims were to evaluate the prognostic relevance, as judged by OS, DFS, and LR, of post-neoadjuvant therapy MRI assessment of tumor stage, nodal status, CRM, and MRI assessment of TRG (mrTRG) system in patients undergoing neoadjuvant therapy and TME surgery in the MERCURY (Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study) trial.
METHODS

Patients
Patients were enrolled onto the original prospective study to evaluate diagnostic accuracy of MRI staging of rectal cancer between February 2002 and October 2003. The local scientific and research ethics committees of each institution approved the study. Eleven specialist colorectal units in five European countries participated in the trial. Consent was sought for continued patient follow-up when the diagnostic accuracy study was completed. 
Inclusion Criteria for This Subgroup Analysis
Biopsy-proven rectal cancer was considered by multidisciplinary team as high risk and requiring preoperative therapy for downstaging or downsizing of the primary tumor staged on baseline pretreatment scans as: advanced T3c, T3d, or T4, potential CRM involvement on MRI. Patients undergoing preoperative chemoradiotherapy or long-course radiotherapy preoperative therapy (n ϭ 111 of 374 patients) were included.
Exclusion Criteria for This Subgroup Analysis
Primary surgery or surgery after short-course preoperative radiotherapy and distant metastatic disease on body computed tomography were exclusion criteria. Contraindications to MRI were also exclusion criteria.
Preoperative Treatment
Preoperative treatment allocated to patients was recorded. All centers offered long-course preoperative therapy for patients with MRI-identified potential CRM involvement. Some centers also offered preoperative therapy (chemoradiotherapy or radiotherapy) for MRI-predicted T3 tumors with adverse features, such as extramural venous invasion, extramural spread greater than 5 mm, or N2 disease.
Radiotherapy consisted of 45 to 54 Gy delivered to the primary tumor and pelviclymphnodesatrisk.Fifty-eightpatientsand53patientsreceivedlong-course radiotherapy or concurrent chemoradiotherapy with a fluoropyrimidine, respectively.MRIscanswereperformedaftercompletionofradiotherapyatanintervalof 4 to 6 weeks, and surgery was undertaken at 6 to 8 weeks after chemoradiotherapy.
Surgery
Surgical options included standard TME plane surgery or extended TME (ie, TME with adjacent visceral resection) with or without sphincter preservation according to a standardized technique. The unit policies were to offer postoperative single-agent chemotherapy for stage III disease. No patient received postoperative radiotherapy.
MRI Assessment
MRI TN stage and circumferential resection margin status after chemoradiotherapy were assessed. A 1-day imaging workshop for specialist gastrointestinal radiologists participating in the study was held before recruitment in 2002 to ensure standardization of scan acquisition techniques (Appendix, online only) and image interpretation before the study, using our published criteria.
2,12,13 All scans were single-read by each investigating center radiologist, comprising 5 to 15 years gastrointestinal radiology experience.
MRI-assessed T staging of tumor post treatment (ymrT) was based on interpretation of local extent of persistent tumor signal intensity relative to the layers of bowel wall on T2-weighted images. T substaging for both MRI (ymrT stage, after preoperative treatment but before surgery) and pathology (ypT stage assessed after surgery) were standardized (Appendix, online only).
Nodal stage post treatment was based on interpretation of lymph node border characteristics and signal intensity.
14 A node was regarded as positive if either an irregular border or mixed signal intensity was demonstrated.
Post-treatment MRI scans were evaluated for predicted circumferential resection margin status (mrCRM). A clear mrCRM was defined if the distance of tumor to the mesorectal fascia was greater than or equal to 1 mm on MRI. For lower-third rectal tumors, the definition of predicted mrCRM involvement was tumor within 1 mm of the levator muscle. If the tumor was present at or below the level of the puborectalis sling, the mrCRM was predicted as involved if there was invasion into the intersphincteric plane or beyond. The mrCRM status was recorded prospectively in the study by each participating radiologist. When a post-treatment scan was not performed, the CRM at baseline was entered as CRM status. All MRI-assessed T, N, and CRM staging data were obtained prospectively by workshop-trained radiologists.
mrTRG
Of 111 patients undergoing preoperative therapy, 92 also underwent posttreatmentMRIbeforesurgery.Sixty-six(72%)of92pre-andpost-treatmentscans were available for central review of mrTRG. MRI scans were made anonymous and were centrally reviewed by a radiologist (G.B.) with 14 years of experience in MRI assessment of rectal cancers by using previously defined criteria.
11
To assess the reproducibility of the mrTRG, pre-and post-treatment scans were reviewed independently by two radiologists (C.D.G. and H.E.) with 5 to 15 years experience in MRI staging of rectal cancers and were compared with the reviews of the central reviewer.
mrTRG was based on similar principles to the pathologic TRG originally described by Dworak et al. 4 Scans were reviewed to determine the degree of tumor replacement by fibrotic stroma (Appendix Fig A1, online only) . 
Histopathologic Assessment
After TME, the specimen was axially sectioned into 3-to 5-mm slices, as described by Quirke et al. 15 A clear pathologic CRM (pCRM) was defined as greater than or equal to 1 mm between the tumor and the resection margin. Eighteen pathologists with 5 to 25 years of experience in GI pathology evaluated the resected specimens for the post-treatment T and N stages (ie, ypT and ypN, respectively) and the circumferential margin status (ie, pCRM). 
Analysis of Data
Tumors were categorized into good and poor responders to enable binary comparison by multivariate analysis. On the basis of known histopathologic outcomes according to ypT stage, good ypT or ymrT stage was defined as stages T0, T1, T2, and T3a; poor was defined as ypT or ymrT stages T3b, T3c, T3d, or T4. Stages T3a and T2 tumors have similar outcomes and therefore are classified as good. 16, 17 MRI-predicted involvement of CRM and pCRM involved were defined as poor, whereas clear pCRM and mrCRM were classified as good. Both mrTRG-4 (predominantly tumor signal intensity with minimal fibrotic lowsignal intensity) and -5 (no fibrosis evident; tumor signal visible only) included patients who had predominant tumor and minimal/no fibrosis; these were defined as poor, whereas mrTRG-1 (absence of any tumor signal) to mrTRG-3 (mixed areas of low-signal fibrosis and intermediate signal intensity present but without predominance of tumor signal) included patients who had 50% or greater fibrotic stroma and therefore were defined as good. Pathologic TRG was not undertaken.
Follow-Up
Patients were observed according to local protocols; typically, this comprised outpatient assessment at intervals of 3 months for a duration of 2 years then intervals of 6 months for a duration of 5 years. Clinical follow-up comprised physical examination, routine blood tests, and yearly computed tomography of the thorax, abdomen, and pelvis. Histopathologic confirmation of LR and distant recurrence was sought when feasible. The surgical data, date of operation, procedure performed, and quality of the specimen were recorded prospectively. Date of enrollment, last follow-up, date of disease progression, and date and cause of death were also collected. The presence of distant metastatic disease or LR at the time of death was recorded as rectal cancerspecific death.
Statistical Analysis
LR was measured from date of original trial enrollment until local progression; DFS was measured from date of enrollment until progression at any site or death as a result of any cause; patients who were alive and disease free were censored at last follow-up or death.
Cox proportional hazard models were used to analyze the effect on LR, DFS, and OS by preoperative MRI staging variables (ie, ymrT, ymrN, mrCRM and mrTRG) and pathologic variables (ie, ypT, ypN, pCRM). Other potential factors-age, sex, type of surgery (TME or abdominoperineal resection with TME approach), tumor height (Ͻ 5 cm or Ͼ 5 cm), and treatment (chemoradiotherapy or long-course radiation)-were included in the multivariate analysis for each MRI/pathology staging variable.
Survival curves were calculated by using the Kaplan-Meier product limit method. Differences between survival curves were tested by using the univariate log-rank test. Correlation between ymrT and mrTRG with ypT was calculated by using the Spearman correlation coefficient.
Agreement between the two observers who graded mrTRG was determined by the statistic.
P less than .05 were considered significant. Calculations were performed by using Statistical Package for Social Sciences program, version 18.0 (SPSS, Chicago, IL).
RESULTS
Eighty-one (73%) of 111 patients were considered to have potential mrCRM involvement before neoadjuvant therapy; this was reduced to 47 (42%) of 111 after treatment. The number of mrT3c, T3d, and T4 tumors reduced from 80 of 111 to 54 of 111. Table 1 shows demographic characteristics and survival outcomes of 111 patients included in the analysis. As of December 2008, surviving patients had been observed for a median of 50 months (range, 0.6 to 71 months). All 111 patients had evaluable post-operative pathology and had complete follow-up data. During the follow-up period, 54 patients died; 40 died as a result of cancer-related causes, five died as a result of noncancer deaths, four died as a result of peri-or post-operative causes, and three patients died as a result of unknown causes. Fifty patients had disease progression; 42 patients experienced recurrence with metastatic disease, and eight experienced relapse with LR only. Table 2 summarizes the results of multivariate analysis of known clinical variables-age, sex, height of tumor from anal verge, type of preoperative treatment, and type of operation-according to each of the MRI preoperative staging variables and survival outcomes. The mrTRG was significant for OS and DFS; hazard ratios were 4.40 (95% CI, 1.65 to 11.7) and 3.28 (95% CI, 1.22 to 8.80), respectively. OS at 5 years for patients with poor mrTRG was 27% (95% CI, 8% to 47%) compared with 72% (95% CI, 56% to 88%) for patients with good mrTRG (P ϭ .001 on univariate log-rank analysis). DFS at 5 years for patients with poor mrTRG was 31% (95% CI, 13% to 49%) compared with 64% (95% CI, 47% to 82%) for patients with good mrTRG (P ϭ .007 on univariate log-rank analysis).
On multivariate analysis, post-treatment prediction of mrCRM was significant for LR. The hazard ratio for predicted involved mr-CRM and LR was 4.25 (95% CI, 1.45 to 12.51). LR rates at 5 years for patients with predicted involved mrCRM was 28% (95% CI, 13% to 44%) compared with 12% (95% CI, 3% to 22%) for patients with predicted clear mrCRM (P ϭ .013 on univariate log-rank analysis).
On multivariate analysis, post-treatment prediction of mrN showed borderline statistical significance for OS and DFS, but it was not significant for LR. Hazard ratios were 1.89 (95% CI, 1.006 to 3.58) and 2.09 (95% CI, 1.06 to 4.15) for OS and DFS, respectively. Table 3 summarizes results of multivariate analysis of association between OS, DFS, and time to LR of known clinical variables-age, sex, height of tumor from anal verge, type of preoperative treatment, and type of operation-according to each of the histopathologic staging variables. On multivariate analysis, ypT remained significant for OS, DFS, and LR; hazard ratios for poor ypT and OS, DFS, and LR were 4.59 (95% CI, 2.16 to 9.78), 5.63 (95% CI, 2.45 to 12.9), and 9.78 (95% CI, 2.29 to 41.8), respectively. Kaplan-Meier survival curves according to ypT stage are shown in Figure 2 .
The 5-year OS for patients with poor ypT was 39% (95% CI, 26% to 51%) compared with 76% (95% CI, 62% to 89%) for good ypT response (P ϭ .0001 on univariate log-rank analysis). The 5-year DFS for patients with poor ypT was 38% (95% CI, 25% to 51%) compared with 84% (95% CI, 72% to 96%) good ypT response (P ϭ .0001 on univariate log-rank analysis). The 5-year LR rate was 27% (95% CI, 14% to 40%) for patients with poor ypT compared with 6% (95% CI, 0% to 15%) for good ypT response (P ϭ .018 on univariate logrank analysis). Abbreviations: AP, abdominoperineal excision; DFS, disease-free survival; HR, hazard ratio; LCRT, long-course chemoradiotherapy; LR, local recurrence; OS, overall survival; pCRM, pathology circumferential resection margin status; RT, radiotherapy; ypN, pathologic N stage post treatment; ypT, pathologic T stage post treatment.
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On multivariate analysis, pCRM was significant for OS, DFS, and LR. Hazard ratios were 2.99 (95% CI, 1.64 to 5.47), 2.17 (95% CI, 1.14 to 4.13), and 8.80 (95% CI, 2.99 to 25.91) respectively.
The 5-year OS for patients with involved pCRM was 30% (95% CI, 10% to 49%) compared with 59% (95% CI, 49% to 70%) for patients with clear pCRM (P ϭ .001 on univariate log-rank analysis). The 5-year DFS for patients with involved pCRM was 28% (95% CI, 7% to 50%) compared with 62% (95% CI, 51% to 73%) for patients with clear pCRM (P ϭ .023 on univariate log-rank analysis). The 5-year LR rate was 56% (95% CI, 30% to 83%) for patients with involved pCRM compared with 10% (95% CI, 3% to 18%) for patients with clear pCRM (P ϭ .0001 on univariate log-rank analysis). MRI staging compared with pathology CRM is shown in Appendix Table A1 (online only).
The ypN did not predict for any of the survival outcomes. The correlation coefficient between mrTRG and ypT of 0.65 was greater than the correlation between ymrT and ypT of 0.48. The linear between radiologists G.B. and C.D.G. was 0.65 (95% CI, 0.44 to 0.86), which indicated moderate to substantial agreement. The linear between radiologists G.B. and H.E. was 0.6 (95% CI, 0.31 to 0.89), which indicated moderate agreement.
DISCUSSION
MRI assessment of TRG after preoperative therapy predicts DFS and OS, and thus patient prognosis, before definitive surgery. Posttreatment MRI prediction of CRM involvement also gives important prognostic information regarding the risk of LR. Our data also show that both MRI T staging and TRG showed statistical correlation with ypT. Results for T staging are consistent with recently published series. 7 However, it appears that the degree of tumor replacement by fibrosis correlates with survival at a greater statistical significance than ymrT stage does. Our experience suggests that assessing the degree of tumor replacement by fibrosis is more reliable than attempting to delineate T stage on MRI after treatment.
There are several pathologic TRG systems (eg, those proposed by Dworak et al, 4 and Mandard et al 6 ), but all are based on the relative proportion of fibrosis present in the resected specimen. The relationship between pathologic TRG and outcome has been considered important in previous studies, 18, 19 for example, in predicting OS and DFS.
6 Applying similar principles with MRI, we have now shown that it is possible to assess tumor regression before surgery.
It is notable that neither histopathologic nor MRI assessment of nodal status after radiotherapy or chemoradiotherapy predicted LR, and this differs from previously published studies. 20, 21 Studies from the pre-TME era convincingly demonstrate the strong relationship between node positivity and pelvic recurrence, which has been attributed to mesorectal tissue containing nodes and deposits left behind in the pelvis. 22 However, incomplete TME specimens are also associated with 20% pelvic recurrence rates for node-positive patients compared with only 6% for complete TME specimens. 23 In the MERCURY study, the TME specimen quality was audited, and an incomplete rate of only 5% was observed, which is significantly better than previously published series. 9, 23, 24 This may explain the observed lack of an effect on outcome by involved lymph nodes influencing pelvic recurrence after preoperative therapy.
The histopathologic variables of T staging and CRM involvement both predicted OS, DFS, and LR. pCRM has previously been described as a crucial prognostic factor after treatment. 25 Our data showed that, of the 23 of 111 patients who had a positive CRM on histopathology, 21 (91%) of the 23 also had diseases staged as ypT poor (Ͼ ypT3a). Thus, the two variables are highly interdependent, and nearly all those patients with involved resection margins were part of the larger poorprognosis group (n ϭ 70) associated with more advanced pathologic T stage.
The strengths of this study are that it represents high-quality radiologic, pathologic, and surgical data ensured by training workshops. The prospective nature of the study also represents a large series of patients who have undergone baseline and post-treatment (ie, chemoradiotherapy) MRI imaging as well as outcome data. However, there are potential limitations of this study. First, 66 (72%) of 92 post-treatment MRI scans were available for a retrospective review of mrTRG. Despite this, a representative sample were reviewed, and interobserver agreement was moderate to substantial ( ϭ 0.6 and 0.65, respectively), indicating that this technique is reproducible. Nevertheless, prospective validation of TRG in predicting outcomes in future studies will confirm its value. An additional limitation was lack of standardization of neoadjuvant therapy and use of both chemoradiotherapy and radiotherapy treatment approaches. Clearly, this could have influenced outcomes, and it would have been expected that patient receiving long-course radiotherapy would have responded less well. However, on multivariate analysis, the type of treatment did not materially influence the outcomes, and the prognostic importance of mrTRG and ypT are independent of the type of treatment received. This is the first time that a prospective study has demonstrated a correlation between radiologically determined tumor response and long-term outcomes. That this is achieved before surgical resection provides evidence for the design of future studies that could alter patient therapy on the basis of response assessment. It also allows identification of good and poor response groups and different approaches that could be adopted after completion of chemoradiotherapy. For example, the role of systemic non-cross-resistant chemotherapy could be tested in patients with poor response, and the evaluation of the timing or even deferral of surgical resection could be tested in patients with good response (ie, mrTRG-1 and -2). 26 Therefore, post-treatment MRI TRG and CRM evaluation gives the multidisciplinary team a window of opportunity to refine treatment plans before definitive surgical treatment.
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